Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL220687 | 0.93 | CA12 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL457477 | 0.93 | — | — | |
| SCHEMBL7548526 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7549199 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7551125 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7541404 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7527051 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8260233 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7548673 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8259026 | 0.91 | CA12 (0.47) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-2653468-B1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8962868-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-2460801-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614340-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICALS CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2653468-A1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2460801-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2011131613-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | CA12 1424/4885CA1 1565/4885CA2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.